Stoke Therapeutics appoints Ian F. Smith as permanent CEO; interim role since March 2025

Stoke Therapeutics, Inc.

Ian F. Smith, 59, appointed CEO effective Oct 6, 2025; served as interim CEO since March 19, 2025.
Annual base salary of $715,000; eligible for annual bonus target of 65% of base salary (no 2025 bonus).
Receives $500,000 sign-on bonus (repayable if resigns within 12 months) and $500,000 performance bonus based on metrics.
Equity grant: option for 570,000 shares (4-yr vest) and RSU for 380,000 shares (4-yr annual vest).
Dr. Tzianabos resigns as Interim Executive Chair, resumes as independent director and Chair of the Board.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.